TORONTO, June 9 - Canadian biotech companies, including the country's burgeoning genomics sector, will likely undergo intense consolidation if they remain unable to balance their huge R&D spending with new types of revenue, according to an Ernst & Young report released today.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.